QHSLab Integrates Digital Medicine Assessments Into Prominent Electronic Health Record (EHR) Company
QHSLab Integrates Digital Medicine Assessments Into Prominent Electronic Health Record (EHR) Company
This integration allows QHSLab access to more than 160,000 providers that are the exact match for target providers.
这种集成允许QHSlab访问超过160,000家与目标提供商完全匹配的提供商。
WEST PALM BEACH, FL, Jan. 30, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the "Company") (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point-of-care technologies, is proud to announce the seamless integration of its digital medicine assessments with one of the nation's top Electronic Health Record (EHR) Company. This update demonstrates promising growth for QHSLab in its mission to revolutionize provider workflow and elevate the quality of patient care.
佛罗里达州西棕榈滩,2024年1月30日(GLOBE NEWSWIRE)——QHSlab, Inc.(“公司”)(OTCQB:USAQ)是一家专注于通过新兴的数字医疗和即时医疗技术为临床医生提供工具的公司,该公司自豪地宣布其数字医学评估与美国顶级电子健康记录(EHR)公司之一无缝整合。此次更新表明,QHSlab在革新提供者工作流程和提高患者护理质量的使命方面取得了可观的发展。
The more than 160,000 providers utilizing this EHR system will now have direct access to QHSLab's comprehensive suite of digital medicine assessments and monitoring tools, such as self-management patient education interventions designed to offer healthcare providers a comprehensive view of their patient's total health. As an added benefit, these practitioners will also have point-of-care testing kits for one of today's most common complaints in general medicine – allergies. With the addition of the AllergiQT, physicians can confirm a patient's allergies with an easy in-office allergy skin test in less than 20 minutes.
现在,使用该EHR系统的160,000多家提供商将可以直接访问QHSlab的全套数字医学评估和监测工具,例如旨在为医疗保健提供者提供患者总体健康状况的自我管理患者教育干预措施。作为额外的好处,这些从业者还将为当今普通医学中最常见的症状之一——过敏提供即时检测试剂盒。加入 AllergiQT 后,医生可以在不到 20 分钟的时间内通过简单的办公室皮肤过敏测试来确认患者的过敏情况。
Key Advantages for Providers and Patients:
提供者和患者的主要优势:
Enhanced Efficiency: Providers will now seamlessly access and review patient assessments within the EHR, negating the need to switch between multiple platforms. This integration simplifies workflow, saving crucial time and reducing administrative burdens, providing healthcare professionals with the bandwidth for better patient care.
提高效率:提供商现在将无缝访问和审查EHR中的患者评估,无需在多个平台之间切换。这种集成简化了工作流程,节省了关键时间并减轻了管理负担,为医疗保健专业人员提供了更好的患者护理所需的带宽。
Informed Decision-Making: Integrating QHSLab's digital assessments within the EHR guarantees providers immediate access to comprehensive patient data. This empowers clinicians to make well-informed decisions, translating into more personalized and effective patient care plans.
知情决策:将QHSlab的数字评估集成到EHR中可确保提供商立即访问全面的患者数据。这使临床医生能够做出明智的决定,转化为更加个性化和有效的患者护理计划。
Real-Time Updates: Patient health is dynamic, and QHSLab provides an ongoing snapshot of a patient's reported feedback and complaints in real time. Patient data remains consistently updated, with changes in QHSLab's assessments automatically reflected in the EHR. This ensures healthcare providers can access the most current information when making clinical decisions and care coordination treatment plans.
实时更新:患者健康状况是动态的,qhsLab实时提供患者报告的反馈和投诉的持续快照。患者数据保持持续更新,QHSlab评估的变化会自动反映在EHR中。这确保了医疗保健提供者在制定临床决策和护理协调治疗计划时可以访问最新的信息。
Seamless Collaboration: The integration fosters a collaborative approach to patient care. Providers can easily share and access patient assessments, nurturing a more connected healthcare ecosystem.
无缝协作:这种整合促进了患者护理的协作方法。提供商可以轻松共享和访问患者评估,从而培育更加互联的医疗保健生态系统。
Patient Engagement: Through QHSLab's digital assessments, patients actively engage in their healthcare journey. They can effortlessly complete assessments from their homes, making healthcare more convenient and accessible. This active involvement has the potential to yield superior patient outcomes. QHSLab also offers a suite of reimbursable assessments and interventions that allow practices to sustain themselves with a new revenue stream through the Company's proven CPT code reimbursement strategy.
患者参与:通过QHSlab的数字评估,患者积极参与他们的医疗之旅。他们可以毫不费力地在家中完成评估,从而使医疗保健更加便捷和可及。这种积极参与有可能为患者带来更好的预后。QHSlab还提供了一套可报销的评估和干预措施,使诊所能够通过公司久经考验的CPT代码报销策略维持生计,获得新的收入来源。
Troy Grogan, Chief Executive Officer at QHSLab, expressed his enthusiasm about this integration: "This collaboration represents a significant milestone for QHSLab. By merging our digital medicine services with EHRs of this caliber, we're redefining how healthcare providers deliver patient care and reaching a broad, new audience for our platform. We've demonstrated a proven track record of success over the past 12 months, and this integration sets the stage for the next chapter of growth during 2024 and beyond."
QHSlab首席执行官特洛伊·格罗根表达了他对这种整合的热情:“这次合作对QHSlab来说是一个重要的里程碑。通过将我们的数字医疗服务与这种水准的电子健康纪录合并,我们正在重新定义医疗保健提供商如何提供患者护理并为我们的平台吸引广泛的新受众。在过去的12个月中,我们取得了良好的成功记录,这种整合为2024年及以后的下一个增长篇章奠定了基础。”
For more information about QHSLab, please visit
有关 QHSlab 的更多信息,请访问
About QHSLab, Inc.
关于 QHSlab, Inc.
QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients' vital signs and evaluate the effects of prescribed medicines and treatments on patients' health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.'s products and services are designed to help physicians improve patient monitoring and medical care while also improving the revenues of their practice.
QHSlab, Inc.(OTCQB:USAQ)是一家医疗器械公司,为初级保健医生提供数字医疗解决方案和即时诊断测试。数字医疗保健使医生能够使用先进的人工智能算法快速有效地评估患者的反应。数字医疗还可以通过患者之间传输的实时数据,远程监控患者的生命体征,评估处方药和治疗对患者健康的影响。QHSlab, Inc. 还营销和销售用于初级保健实践的即时快速反应诊断测试。qHSlab, Inc. '的产品和服务旨在帮助医生改善患者监测和医疗护理,同时提高他们的诊所收入。
Forward-Looking Statements
前瞻性陈述
Certain matters discussed in this press release are 'forward-looking statements' intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as 'may,' 'could,' 'believes,' 'estimates,' 'targets,' 'expects,' or 'intends,' and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
本新闻稿中讨论的某些事项是 “前瞻性陈述”,旨在使他们有资格获得安全港,免于承担1995年《私人证券诉讼改革法》规定的责任。特别是,公司关于市场趋势、未来收入、未来产品以及潜在未来业绩和收购的陈述就是此类前瞻性陈述的示例。前瞻性陈述通常用 “可能”、“可能”、“相信”、“估计”、“目标”、“预期” 或 “打算” 等词语以及其他表达风险和不确定性的类似词语来识别。这些陈述受到许多风险和不确定性的影响,包括但不限于新产品的推出时间、管理层的估计、预测和预测与实际业绩的固有差异、监管延误、政府资金和预算的变化以及公司无法控制的其他因素,包括总体经济状况。本文讨论并在公司向美国证券交易委员会提交的文件中不时表达的因素可能导致实际业绩和发展与此类声明中表达或暗示的业绩和发展存在重大差异。前瞻性陈述仅在本新闻稿发布之日作出。公司没有义务公开更新此类前瞻性陈述以反映随后的事件或情况。
Investor Relations Contact:
投资者关系联系人:
Olivia Giamanco
QHSLab, Inc.
(929) 379-6503
ir@usaqcorp.com
奥利维亚·贾曼科
qHSlab, Inc.
(929) 379-6503
ir@usaqcorp.com